Abstract
Patients with renal stones are known to be at risk of clinical complications such as cardiovascular disease (CVD), nephropathy, and cancer. Recently, it has been realized that almost all risk markers for CVD, nephropathy, etc. are all markers associated with the sequence of reactions of chronic inflammation. It has been reported that chronic inflammation is involved not only in the pathogenesis of nephrolithiasis but also contributes to the development of clinical complications in this condition; therefore, we decided to find out whether these multiple markers are detectable in patients with renal stones so that they can be used to predict the risk of clinical complications in these patients. There were 33 patients with nephrolithiasis included in this study. We found that almost all major markers of chronic inflammation were elevated in patients with renal stones, including proinflammatory cytokine, acute inflammation markers, adhesion molecules, urinary microalbumin (uMA), myeloperoxidase (MPO), 8‐hydroxydeoxyguanosine (8‐OHdG), 3‐nitrotyrosine (3NT), and monocyte chemoattractant protein. It appears that it is possible to assess the risk of clinical complications by monitoring these markers in patients with renal stones. J. Clin. Lab. Anal. 21:426–431, 2007. © 2007 Wiley‐Liss, Inc.
Keywords: chronic systemic inflammation, atherogenesis, CVD, renal stones, risk markers, oxidative stress
| Abbreviations | |
|---|---|
| hCRP | high sensitive C‐reactive protein |
| CVD | cardiovascular disease |
| ICAM‐1 | intercellular adhesion molecule |
| IL‐6 | interleukin‐6 |
| MPO | myeloperoxidase |
| ELISA | enzyme linked immunosorbent assay |
| uMA | urinary microalbumin |
| MCP‐1 | monocyte chemoattractant protein |
| 3NT | 3‐nitrotyrosine |
| 8‐OHdG | 8‐hydroxydeoxyguanosine |
| SAA | serum amyloid A |
| VCAM‐1 | vascular cell adhesion molecule |
REFERENCES
- 1. Hamano S, Nakatsu H, Suzuki N, Tomioka S, Tanaka M, Murakami S. Kidney stone disease and risk factors for coronary heart disease. Int J Urol 2005;12:859–863. [DOI] [PubMed] [Google Scholar]
- 2. Vupputuri S, Soucie JM, McClellan W, Sandler DP. History of kidney stones as a possible risk factor for chronic kidney disease. Ann Epidemiol 2004;14:222–228. [DOI] [PubMed] [Google Scholar]
- 3. Raghavendran M, Rastogi A, Dubey D, et al. Stones associated renal pelvic malignancies. Indian J Cancer 2003;40:108–112. [PubMed] [Google Scholar]
- 4. Kayaselcuk F, Bal N, Guvel S, Egilmez T, Kilinc F, Tuncer I. Carcinosarcoma and squamous cell carcinoma of the renal pelvis associated with nephrolithiasis: a case report of each tumor type. Pathol Res Pract 2003;199:489–492. [DOI] [PubMed] [Google Scholar]
- 5. Ramey SL, Franke WD, Shelley MC 2nd. Relationship among risk factors for nephrolithiasis, cardiovascular disease, and ethnicity: focus on a law enforcement cohort. AAOHN J 2004;52:116–121. [PubMed] [Google Scholar]
- 6. Khan SR, Kok DJ. Modulators of urinary stone formation. Front Biosci 2004;9:1450–1482. [DOI] [PubMed] [Google Scholar]
- 7. Khan SR. Hyperoxaluria‐induced oxidative stress and antioxidants for renal protection. Urol Res 2005;33:349–357. [DOI] [PubMed] [Google Scholar]
- 8. Srinivasan S, Pragasam V, Jenita X, Kalaiselvi P, Muthu V, Varalakshmi P. Oxidative stress in urogenital tuberculosis patients: a predisposing factor for renal stone formation‐amelioration by vitamin E supplementation. Clin Chim Acta 2004;350:57–63. [DOI] [PubMed] [Google Scholar]
- 9. Huang HS, Ma MC, Chen CF, Chen J. Changes in nitric oxide production in the rat kidney due to CaOx nephrolithiasis. Neurourol Urodyn 2006;25:252–258. [DOI] [PubMed] [Google Scholar]
- 10. Aihara K, Byer KJ, Khan SR. Calcium phosphate‐induced renal epithelial injury and stone formation: involvement of reactive oxygen species. Kidney Int 2003;64:1283–1291. [DOI] [PubMed] [Google Scholar]
- 11. Wu JT, Wu LL. Linking inflammation and atherogenesis: soluble markers identified for the detection of risk factors and for early risk assessment. Clin Chim Acta 2006;366:74–80. [DOI] [PubMed] [Google Scholar]
- 12. Honda H, Qureshi AR, Heimburger O, et al. Serum albumin, C‐reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006;47:139–148. [DOI] [PubMed] [Google Scholar]
- 13. Ridker PM, Hennekens CH, Buring JE, Rifai N. C‐reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836–843. [DOI] [PubMed] [Google Scholar]
- 14. Johnson BD, Kip KE, Marroquin OC, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute‐Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004;109:726–732. [DOI] [PubMed] [Google Scholar]
- 15. Jude EB, Douglas JT, Anderson SG, Young MJ, Boulton AJ. Circulating cellular adhesion molecules ICAM‐1, VCAM‐1, P‐ and E‐selectin in the prediction of cardiovascular disease in diabetes mellitus. Eur J Intern Med 2002;13:185–189. [DOI] [PubMed] [Google Scholar]
- 16. Wu TL, Chang PY, Li CC, Tsao KC, Sun CF, Wu JT. Microplate ELISA for urine microalbumin: reference values and results in patients with type 2 diabetes and cardiovascular disease. Ann Clin Lab Sci 2005;35:149–154. [PubMed] [Google Scholar]
- 17. Brennan ML, Hazen SL. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Curr Opin Lipidol 2003;14:353–359. [DOI] [PubMed] [Google Scholar]
- 18. Kooy NW, Lewis SJ, Royall JA, Ye YZ, Kelly DR, Beckman JS. Extensive tyrosine nitration in human myocardial inflammation: evidence for the presence of peroxynitrite. Crit Care Med 1997;25:812–819. [DOI] [PubMed] [Google Scholar]
- 19. Yuyun MF, Khaw KT, Luben R, et al. Microalbuminuria independently predicts all‐cause and cardiovascular mortality in a British population: the European Prospective Investigation into Cancer in Norfolk (EPIC‐Norfolk) population study. Int J Epidemiol 2004;33:189–198. [DOI] [PubMed] [Google Scholar]
- 20. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868–874. [DOI] [PubMed] [Google Scholar]
- 21. Wu T‐L, Chang P‐Y, Li C‐N, Tsao K‐C, Sun C‐F, Wu JT. Development of ELISA on microplate for C‐reactive protein and establishment of age‐dependent normal reference range. Clin Chim Acta 2002;322:163–166. [DOI] [PubMed] [Google Scholar]
- 22. Wu T‐L, Tsai IC, Chang P‐Y, et al. Establishment of an in‐house ELISA and the reference range for serum amyloid A (SAA). Complementary between SAA and C‐reactive protein as markers of inflammation. Clin Chim Acta 2006;376:72–76. [DOI] [PubMed] [Google Scholar]
- 23. Chang P‐Y, Wu T‐L, Tsao K‐C, Li CC, Sun CF, Wu JT. Establishment of ELISAs on microplate for soluble VCAM‐1 and ICAM. Ann Clin Lab Sci 2005;35:312–317. [PubMed] [Google Scholar]
- 24. Tsao K‐C, Chang P‐Y, Li CC, Wu T‐L, Sun C‐F, Wu JT. Development of an ELISA on microplate for circulating E‐selectin: assay characterization, comparison with commercial kit and establishment of normal reference values. J Clin Lab Anal 2003;17:97–101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Chiou C‐C, Chang P‐Y, Chan E‐C, Wu T‐L, Tsao K‐C, Wu JT. Urinary 8‐hydroxydeoxyguanosine and its analogs as DNA marker of oxidative stress: development of an ELISA and measurement in both bladder and prostate cancers. Clin Chim Acta 2003;334:87–94. [DOI] [PubMed] [Google Scholar]
- 26. Chang P‐Y, Wu T‐L, Hung C‐C, et al. Development of an ELISA for myeloperoxidase on microplate: normal reference value and effect of temperature on specimen preparation. Clin Chim Acta 2006;373:158–163. [DOI] [PubMed] [Google Scholar]
- 27. Sun Y‐C, Chang PY, Tsao K‐C, et al. Establishment of a sandwich ELISA using commercial antibody for plasma or serum 3‐nitrotyrosine (3NT). Elevation in inflammatory diseases and complementary between 3NT and myeloperoxidase. Clin Chim Acta 2007;378:175–180. [DOI] [PubMed] [Google Scholar]
- 28. Wu T‐L, Sun YC, Hung CC, Chang PY, Wu JT. Development of an ELISA for serum IL‐6 and determination of its serum level in healthy person and patients with type 2 diabetes. Clin Chem 2005;51:A7. [Google Scholar]
- 29. Tsai IC, Huang YC, Chang PY, Wu TL, Wu JT. Establishment of two ELISA for MCP‐1 and M‐CSF and their measurements in patients with acute myocardial Infraction. Presented at the Annual Conference of the Taiwan Society of Laboratory Medicine, Taipei, Taiwan, November 18–19, 2006. [Google Scholar]
- 30. Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM‐1, but not ICAM‐1, in early atherosclerosis. J Clin Invest 2001;107:1255–1262. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity‐onset diabetes. N Engl J Med 1984;310:356–360. [DOI] [PubMed] [Google Scholar]
- 32. Lim SC, Caballero AE, Smakowski P, LoGerfo FW, Horton ES, Veves A. Soluble intercellular adhesion molecule, vascular cell adhesion molecule, and impaired microvascular reactivity are early markers of vasculopathy in type 2 diabetic individuals without microalbuminuria. Diabetes Care 1999;22:1865–1870. [DOI] [PubMed] [Google Scholar]
- 33. Ritz E. Albuminuria and vascular damage—the vicious twins. Editorials. N Engl J Med 2003;348:2349–2352. [DOI] [PubMed] [Google Scholar]
- 34. Umekawa T, Chegini N, Khan SR. Increased expression of monocyte chemoattractant protein‐1 (MCP‐1) by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals. Nephrol Dial Transplant 2003;18:664–669. [DOI] [PubMed] [Google Scholar]
- 35. Liu E, Sakoda LC, Gao YT, et al. Aspirin use and risk of biliary tract cancer: a population‐based study in Shanghai, China. Cancer Epidemiol Biomarkers Prev 2005;14:1315–1318. [DOI] [PubMed] [Google Scholar]
- 36. Itoh Y, Yasui T, Okada A, Tozawa K, Hayashi Y, Kohri K. Preventive effects of green tea on renal stone formation and the role of oxidative stress in nephrolithiasis. J Urol 2005;173:271–275. [DOI] [PubMed] [Google Scholar]
- 37. Srinivasan S, Pragasam V, Jenita X, Kalaiselvi P, Muthu V, Varalakshmi P. Oxidative stress in urogenital tuberculosis patients: a predisposing factor for renal stone formation—amelioration by vitamin E supplementation. Clin Chim Acta 2004;350:57–63. [DOI] [PubMed] [Google Scholar]